TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12168123

Group type: EXPERIMENTAL
Intervention: Pressure support ventilation with volume guarantee (PSV+VG)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation (SIMV)
Number of subjects: 14
Study: 10435066

Group type: EXPERIMENTAL
Intervention: Oestradiol therapy (2 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 7501671

Group type: EXPERIMENTAL
Intervention: 2 mg/kg caffeine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6 mg/kg caffeine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2182444

Group type: EXPERIMENTAL
Intervention: 18 Gy cranial irradiation
Number of subjects: 1165

Group type: EXPERIMENTAL
Intervention: Intermediate-dose i.v. methotrexate (ID-MTX) (4 x 0.5 g/m2)
Number of subjects: 1165

Group type: COMPARATOR
Intervention: No irradiation
Number of subjects: 1165

Group type: EXPERIMENTAL
Intervention: 12 Gy or 18 Gy cranial irradiation
Number of subjects: 1165

Group type: EXPERIMENTAL
Intervention: Intensive reinduction regimen (protocol III)
Number of subjects: 1165

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 1165
Study: 7028208

Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 31601514

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg/d
Number of subjects: 1110

Group type: COMPARATOR
Intervention: Sunitinib 50 mg/d, 4 weeks on/2 weeks off
Number of subjects: 1110

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg/d without AE-related dose reductions
Number of subjects: 1110

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg/d with AE-related dose reductions
Number of subjects: 1110

Group type: COMPARATOR
Intervention: Sunitinib 50 mg/d without AE-related dose reductions
Number of subjects: 1110

Group type: COMPARATOR
Intervention: Sunitinib 50 mg/d with AE-related dose reductions
Number of subjects: 1110
Study: 28935273

Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol (EP) administered every 21 days (q21d)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol (EP)
Number of subjects: 139
Study: 26827187

Group type: EXPERIMENTAL
Intervention: Real 1.0 mA tDCS over sensory cortex for 20 min
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 60
Study: 24846279

Group type: EXPERIMENTAL
Intervention: Serum levels of K18 in adults with histologic improvement at week 96
Number of subjects: 383

Group type: COMPARATOR
Intervention: Serum levels of K18 in adults without histologic improvement
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Serum levels of K18 in children with histologic improvements at week 48
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Serum levels of K18 in children with histologic improvements at week 96
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Serum levels of K18 in adults
Number of subjects: 383

Group type: COMPARATOR
Intervention: Alanine aminotransferase levels in adults
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Serum levels of K18 in children
Number of subjects: 383

Group type: COMPARATOR
Intervention: Alanine aminotransferase levels in children
Number of subjects: 383
Study: 22487036

Group type: EXPERIMENTAL
Intervention: Long decision time condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short decision time condition
Number of subjects: 0
Study: 19543499

Group type: EXPERIMENTAL
Intervention: Rush immunotherapy (RIT) with Dermatophagoides farinae (Der f) and Dermatophagoides pteronyssinus (Der p)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no RIT)
Number of subjects: 15
Study: 17292595

Group type: EXPERIMENTAL
Intervention: TJ‐114 (Saireito) at a dose of 9 g/day for 2 days before surgery and for 2 weeks after surgery
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: TJ‐114 (Saireito)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no TJ‐114)
Number of subjects: 17
Study: 15308514

Group type: COMPARATOR
Intervention: CT guided suprascapular nerve block with methylprednisolone acetate and bupivacaine
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Anatomical landmark approach suprascapular nerve block
Number of subjects: 67
Study: 11354593

Group type: EXPERIMENTAL
Intervention: Problem-solving remediation (10 sessions)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Memory training (10 sessions)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 9742275

Group type: EXPERIMENTAL
Intervention: d,l-methadone
Number of subjects: 40

Group type: COMPARATOR
Intervention: l-methadone
Number of subjects: 40
Study: 8113113

Group type: EXPERIMENTAL
Intervention: Sucralfate suspension
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 3289768

Group type: EXPERIMENTAL
Intervention: Continuous epidural analgesia (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intermittent epidural analgesia (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 29944651

Group type: EXPERIMENTAL
Intervention: Single-dose oral ciprofloxacin for household contacts within 24 hours of case notification
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Village-wide distribution of ciprofloxacin within 72 hours of first case notification
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard care (control arm)
Number of subjects: 49
Study: 28780509

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention
Number of subjects: 1137
Study: 26020438

Group type: EXPERIMENTAL
Intervention: Low-radiation-dose CT images scored by eight radiologists using morphologic categories proposed by the Fleischner Society guidelines.
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Nodule categorization as part‐solid nodules and location in the upper lobe.
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: All possible reading pairs (28 possible combinations of observer pairs x 160 nodules = 4480 possible agreements or disagreements).
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Discrepant readings of nodule classification.
Number of subjects: 160
Study: 23358975

Group type: EXPERIMENTAL
Intervention: Problem‐solving skills training (PSST)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Nondirective support (NDS)
Number of subjects: 309
Study: 21362684

Group type: EXPERIMENTAL
Intervention: Timing oocyte collection when the leading follicle had a diameter of 22 mm
Number of subjects: 190
Study: 19170143

Group type: EXPERIMENTAL
Intervention: C. colocynthis fruit capsules (100 mg, three times a day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 16824998

Group type: EXPERIMENTAL
Intervention: RT3DE with contrast enhancement
Number of subjects: 24

Group type: COMPARATOR
Intervention: RT3DE without contrast
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: RT3DE with good endocardial definition
Number of subjects: 24
Study: 12895212

Group type: EXPERIMENTAL
Intervention: Anti-H. pylori therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: H. pylori negative status
Number of subjects: 24
Study: 10705200

Group type: EXPERIMENTAL
Intervention: Combined androgen blockade (CAB) with goserelin acetate 3.6 mg and flutamide 250 mg three times daily
Number of subjects: 589

Group type: COMPARATOR
Intervention: Goserelin acetate 3.6 mg alone
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Combined androgen blockade (CAB)
Number of subjects: 589
Study: 9161864

Group type: EXPERIMENTAL
Intervention: Tsumura Chorei‐to
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 74
Study: 8477016

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 30
Study: 3530176

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (VCR, NMM, Act.‐D)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (VCR, NMM, Act.‐D, DTIC)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (VCR, Act.‐D, CCNU, DTIC)
Number of subjects: 92

Group type: COMPARATOR
Intervention: DTIC-monotherapy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Cross over treatment after progression
Number of subjects: 92
Study: 30520854

Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 291

Group type: COMPARATOR
Intervention: No statin treatment
Number of subjects: 291
Study: 27494917

Group type: EXPERIMENTAL
Intervention: Rapid review by a multidisciplinary antimicrobial stewardship team (intervention arm)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard care (control arm)
Number of subjects: 160
Study: 24170750

Group type: EXPERIMENTAL
Intervention: Intervention to reduce regimen distress (RD)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Baseline RD
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Baseline medication adherence
Number of subjects: 392
Study: 22271776

Group type: EXPERIMENTAL
Intervention: IRT/PAP approach
Number of subjects: 145499

Group type: EXPERIMENTAL
Intervention: IRT/DNA/sequencing strategy
Number of subjects: 145499

Group type: EXPERIMENTAL
Intervention: Combined strategy (IRT/PAP/DNA/sequencing)
Number of subjects: 145499
Study: 20200301

Group type: EXPERIMENTAL
Intervention: Insulin glargine once daily
Number of subjects: 973

Group type: COMPARATOR
Intervention: Insulin detemir twice daily
Number of subjects: 973
Study: 19337555

Group type: EXPERIMENTAL
Intervention: CLAs 2.5 g (2 g mixture of cis 9‐trans 11 and trans 10‐cis12 CLAs)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Vitamin E 400 mg
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: CLAs and vitamin E at above doses
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 15847626

Group type: EXPERIMENTAL
Intervention: Web‐based tailored behavioral smoking cessation materials
Number of subjects: 3971

Group type: COMPARATOR
Intervention: Web‐based non‐tailored materials
Number of subjects: 3971
Study: 12218524

Group type: EXPERIMENTAL
Intervention: Clomethiazole edisilate (0.8%), 225 ml loading dose followed by 100 ml/h maintenance during surgery
Number of subjects: 245

Group type: COMPARATOR
Intervention: 0.9% NaCl (placebo)
Number of subjects: 245
Study: 10334431

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg i.v. verapamil
Number of subjects: 19

Group type: COMPARATOR
Intervention: 0.5 N saline
Number of subjects: 19
Study: 8961125

Group type: EXPERIMENTAL
Intervention: Nicotinamide treatment
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control group (untested)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Refusers (offered testing but did not consent)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Tested group (combined with refusers)
Number of subjects: 173
Study: 1957127

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b treatment (3 million units thrice weekly)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b treatment (6 million units thrice weekly for at least 8 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Biochemical relapse in responders
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Histological assessment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison of responders and non-responders
Number of subjects: 30
Study: 7011348

Group type: EXPERIMENTAL
Intervention: Tiamenidine (3 mg daily)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Clonidine (450 micrograms daily)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Withdrawal of Tiamenidine
Number of subjects: 4

Group type: COMPARATOR
Intervention: Withdrawal of Clonidine
Number of subjects: 4
Study: 30939114

Group type: EXPERIMENTAL
Intervention: Athletes
Number of subjects: 583

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 583
Study: 27875802

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 25414152

Group type: EXPERIMENTAL
Intervention: Treatment for mild GDM
Number of subjects: 500

Group type: COMPARATOR
Intervention: No treatment for mild GDM (Control)
Number of subjects: 500
Study: 23661035

Group type: EXPERIMENTAL
Intervention: Expectations regarding treatment
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Past experience with treatment
Number of subjects: 77
Study: 21122908

Group type: EXPERIMENTAL
Intervention: One-step self-etch adhesive with selective etching of enamel
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (Bond Force adhesive without selective etching)
Number of subjects: 28
Study: 18989348

Group type: EXPERIMENTAL
Intervention: Ruboxistaurin 32 mg/day
Number of subjects: 506

Group type: COMPARATOR
Intervention: Moderate visual loss (MVL)
Number of subjects: 506
Study: 17972425

Group type: EXPERIMENTAL
Intervention: Triple therapy (ACE‐I + BB + ARA or ARB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quadruple therapy (ACE‐I + BB + ARA + ARB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACE‐I and BB combined with diuretics and often with digoxin
Number of subjects: 0
Study: 15118203

Group type: EXPERIMENTAL
Intervention: Random practice group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blocked practice group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-task control group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 12530553

Group type: EXPERIMENTAL
Intervention: Fish oil (3.5 g EPA and 2.4 g DHA per day, each as the ethyl ester)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Evening primrose oil capsules (no detectable EPA or DHA)
Number of subjects: 20
Study: 10326538

Group type: EXPERIMENTAL
Intervention: lamivudine plus zidovudine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: lamivudine plus stavudine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: lamivudine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: stavudine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: zidovudine
Number of subjects: 28
Study: 7622984

Group type: EXPERIMENTAL
Intervention: Novel motion preference after 1 min delay
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Familiar motion preference after 1 month delay
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Intermediate retention intervals (1 day, 2 weeks)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Familiarity preference after 3-month interval
Number of subjects: 194
Study: 2654576

Group type: EXPERIMENTAL
Intervention: Individual counselling by occupational health professionals
Number of subjects: 2489

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2489
Study: 1259046

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30620727

Group type: EXPERIMENTAL
Intervention: Teriparatide (PTH 1–34)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 54
Study: 28684614

Group type: EXPERIMENTAL
Intervention: Qred (200 mg/d)
Number of subjects: 36
Study: 25564194

Group type: EXPERIMENTAL
Intervention: Williams LifeSkills Training (WLST)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (usual intervention)
Number of subjects: 66
Study: 23137063

Group type: COMPARATOR
Intervention: Pulsed-dye laser (PDL) treatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) treatment
Number of subjects: 15
Study: 21523262

Group type: EXPERIMENTAL
Intervention: WPC preparation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19257821

Group type: EXPERIMENTAL
Intervention: Risedronate (15 mg once per week for patients <40 kg; 30 mg once per week for patients >40 kg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 17101701

Group type: EXPERIMENTAL
Intervention: Removable appliance with a palatal crib associated with high-pull chin cup therapy for 12 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study: 16197750

Group type: EXPERIMENTAL
Intervention: Interactive CD only
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Interactive CD and lecture
Number of subjects: 75

Group type: COMPARATOR
Intervention: Lecture only
Number of subjects: 75
Study: 11315834

Group type: EXPERIMENTAL
Intervention: Glucagon (1 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Epinephrine (0.3 mg)
Number of subjects: 10
Study: 9223026

Group type: EXPERIMENTAL
Intervention: NaHCO3 (250 mg (3 mmol).(kg body weight)‐1)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control
Number of subjects: 7
Study: 8192551

Group type: EXPERIMENTAL
Intervention: L-365,260 (50 mg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: L-365,260 (10 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 3359905

Group type: EXPERIMENTAL
Intervention: vodka (37.5 ml) in tomato juice
Number of subjects: 10

Group type: COMPARATOR
Intervention: tomato juice alone
Number of subjects: 10
Study: 31944276

Group type: EXPERIMENTAL
Intervention: Perampanel 4 mg/d
Number of subjects: 979

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 979
Study: 31489825

Group type: EXPERIMENTAL
Intervention: Autistic children
Number of subjects: 407

Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 407
Study: 28179454

Group type: EXPERIMENTAL
Intervention: pembrolizumab 10 mg/kg i.v. every 2 or 3 weeks until disease progression
Number of subjects: 1374

Group type: EXPERIMENTAL
Intervention: pembrolizumab 2 or 10 mg/kg i.v. every 3 weeks
Number of subjects: 1374

Group type: COMPARATOR
Intervention: ipilimumab 3 mg/kg every 3 weeks for up to four doses
Number of subjects: 1374

Group type: COMPARATOR
Intervention: investigator's choice of chemotherapy
Number of subjects: 1374
Study: 25984611

Group type: EXPERIMENTAL
Intervention: 0.75 % ropivacaine infiltrated at the trocar insertion sites and in the gallbladder fossa
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous dipyrone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 23494213

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment program
Number of subjects: 89

Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 89
Study: 21242556

Group type: EXPERIMENTAL
Intervention: EHR-based clinical decision support system
Number of subjects: 2556
Study: 18065809

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg single dose)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg daily for 4 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 17359691

Group type: EXPERIMENTAL
Intervention: Jaundice-reducing group (UPTBD and ENBD)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Non-reducing group (general pre-operation routine preparation)
Number of subjects: 183
Study: 14598035

Group type: EXPERIMENTAL
Intervention: Wender Utah Rating Scale short form (WURS-k)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: WURS-k total score
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: WURS-k individual factors
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Eysenck's Impulsivity Questionnaire (EIQ)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: WURS-k
Number of subjects: 63
Study: 10971238

Group type: COMPARATOR
Intervention: Propofol alone (n=120, group A, loading dose 40-60 mg IV, followed by repeated doses of 20 mg)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Propofol plus midazolam (n=119, group B, initial midazolam dose of 2.5-3.5 mg IV, followed by repeated doses of 20 mg of propofol)
Number of subjects: 239
Study: 8774280

Group type: EXPERIMENTAL
Intervention: Transvaginal 3-D ultrasound evaluation
Number of subjects: 42
Study: 1310922

Group type: EXPERIMENTAL
Intervention: L-(−)-Ephedrine hydrochloride (50 mg three times a day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31479355

Group type: EXPERIMENTAL
Intervention: Moving to Opportunity for Fair Housing Demonstration Program (intervention group)
Number of subjects: 4600

Group type: COMPARATOR
Intervention: Control group (households not receiving the intervention)
Number of subjects: 4600
Study: 30106185

Group type: EXPERIMENTAL
Intervention: Everolimus (EVL) group, N = 96
Number of subjects: 361

Group type: COMPARATOR
Intervention: Calcineurin Inhibition (CNI) group (CsA), N = 89
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: MPS group, N = 39
Number of subjects: 361
Study: 26672637

Group type: EXPERIMENTAL
Intervention: Somavaratan 1.15 mg/kg weekly
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Somavaratan 2.5 mg/kg twice monthly
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Somavaratan 5.0 mg/kg monthly
Number of subjects: 68
Study: 24074143

Group type: EXPERIMENTAL
Intervention: SFC 50/250 via Rotahaler
Number of subjects: 60

Group type: COMPARATOR
Intervention: SFC 50/250 via Diskus
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both inhalers
Number of subjects: 60
Study: 22497929

Group type: EXPERIMENTAL
Intervention: Prehospital stroke treatment in a mobile stroke unit (MSU)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Optimised conventional hospital-based stroke treatment (control group)
Number of subjects: 100
Study: 20155247

Group type: EXPERIMENTAL
Intervention: 200 IU vitamin D(3)/day (intervention group)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 221
Study: 17649769

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 0
Study: 11703549

Group type: EXPERIMENTAL
Intervention: Nurse specialist model
Number of subjects: 99

Group type: COMPARATOR
Intervention: Traditional care model
Number of subjects: 99
Study: 9041371

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 13

Group type: COMPARATOR
Intervention: Pancreatic clamping with constant insulin levels
Number of subjects: 13